Literature DB >> 26669918

Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments.

Laura C Coates1, Philip S Helliwell2.   

Abstract

OBJECTIVE: To explore the relationship between minimal disease activity (MDA) and the low disease activity cutoffs of the Psoriatic ArthritiS Disease Activity Score (PASDAS) and the Composite Psoriatic Disease Activity Index (CPDAI).
METHODS: Data from the GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) composite exercise (GRACE) study were used for these analyses. Alternative definitions of low disease activity were used with 6/7 and 7/7 of MDA items, and a criteria set mandating the 2 articular items and 3/5 alternate items (MDA-joints). Two reference questions were used as anchors: physician's global opinion of MDA, and patient's opinion on their disease control.
RESULTS: Substantial agreement was found between MDA, MDA-joints, PASDAS, and CPDAI. Compared to the 2 reference questions, the various definitions of low disease activity gave sensitivities that were generally worse than specificities, the latter being high (> 0.9) in most cases. Both PASDAS and CPDAI demonstrated good discrimination between the "low" and "high" disease activity states by all the MDA definitions. Using these data, with an MDA of 7/7 to define a very low disease cutoff, the corresponding values for PASDAS and CPDAI were 1.9 and 2, respectively.
CONCLUSION: An MDA score of 7/7 is proposed as very low disease activity in psoriatic arthritis. Using this definition, the equivalent cutoffs for PASDAS and CPDAI are 1.9 and 2, respectively.

Entities:  

Keywords:  LOW DISEASE ACTIVITY; PSORIATIC ARTHRITIS; REMISSION

Mesh:

Year:  2015        PMID: 26669918     DOI: 10.3899/jrheum.150826

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  29 in total

1.  Gender does not make a difference in "composite psoriatic disease activity index (CPDAI)" in patients with psoriatic arthritis.

Authors:  Gökçe Kenar; Handan Yarkan; Berrin Zengin; Gerçek Can; Merih Birlik; Fatoş Önen
Journal:  Rheumatol Int       Date:  2018-09-08       Impact factor: 2.631

Review 2.  Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment.

Authors:  Wolf-Henning Boehncke; Nicolo Costantino Brembilla
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

3.  Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?

Authors:  Gamze Kilic; Erkan Kilic; Kemal Nas; Ayhan Kamanlı; İbrahim Tekeoglu
Journal:  Rheumatol Int       Date:  2018-11-13       Impact factor: 2.631

Review 4.  The Changing Face of Clinical Trials in Psoriatic Arthritis.

Authors:  Alexis Ogdie; Laura Coates
Journal:  Curr Rheumatol Rep       Date:  2017-04       Impact factor: 4.592

5.  Psoriatic arthritis: is it time to treat-to-target or target to treat?

Authors:  Ennio Lubrano; Fabio Massimo Perrotta
Journal:  Clin Rheumatol       Date:  2017-10-24       Impact factor: 2.980

Review 6.  Consensus-based recommendations on the diagnosis, referral and clinical management of patients with psoriatic arthritis.

Authors:  Hanan Al Rayes; Mansour Alazmi; Suzan Attar; Khaled Alderaan; Mushabab Alghamdi; Nayef Alghanim; Ahmed Alhazmi; Nadeer Alkhadhrawi; Mohammad Almohideb; Zeyad Alzahrani; Mohamed Bedaiwi; Hussein Halabi
Journal:  Rheumatol Int       Date:  2021-10-30       Impact factor: 2.631

Review 7.  Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.

Authors:  Laure Gossec; Laura C Coates; Maarten de Wit; Arthur Kavanaugh; Sofia Ramiro; Philip J Mease; Christopher T Ritchlin; Désirée van der Heijde; Josef S Smolen
Journal:  Nat Rev Rheumatol       Date:  2016-11-10       Impact factor: 20.543

Review 8.  Measuring Outcomes in Psoriatic Arthritis.

Authors:  Alexis Ogdie; Laura C Coates; Philip Mease
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-10       Impact factor: 4.794

9.  Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial.

Authors:  Philip J Mease; Arthur Kavanaugh; Laura C Coates; Iain B McInnes; Maja Hojnik; Ying Zhang; Jaclyn K Anderson; Alexander P Dorr; Dafna D Gladman
Journal:  RMD Open       Date:  2017-07-18

10.  Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions.

Authors:  Kemal Nas; Erkan Kiliç; Remzi Çevik; Hatice Bodur; Şebnem Ataman; Figen Ayhan; Özgür Akgül; Ayşen Akinci; Zuhal Altay; Erhan Çapkın; Abdullah Zübeyir Dağli; Tuncay Duruöz; Gülcan Gürer; Feride Göğüş; Yeşim Garip; Cahit Kaçar; Ayhan Kamanli; Ece Kaptanoğlu; Taciser Kaya; Hilal Kocabaş; Erhan Ali Özdemirel; Sumru Özel; İlhan Sezer; İsmihan Sunar; Gürkan Yilmaz
Journal:  Arch Rheumatol       Date:  2018-05-21       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.